|
| Oncothyreon files investigational new drug application for PX-866 oncology compound |
1 May 08, 09:00 |
|
| Oncothyreon Inc. today announced that it has filed an investigational new drug application with the U.S. Food and Drug Administration for PX-866, a small molecule phosphatidylinositol-3-kinase inhibitor for the treatment of advanced cancers. |
| more |
|
